Eli Lilly expands obesity drug access for Medicare patients

Pharmaceutical giant Eli Lilly is set to broaden access to its weight-loss medications for Medicare beneficiaries, a move analysts suggest could significantly influence U.S. healthcare spending and cost trends.

Starting June 30, 2026, eligible Medicare Part D beneficiaries will be able to access Eli Lilly's treatments, Foundayo (orforglipron) and Zepbound (tirzepatide), for a monthly cost of $50. This initiative marks the first program of its kind within Medicare for these types of drugs, known as GLP-1 agonists.

The announcement underscores the rapid adoption and growing market presence of GLP-1 drugs, which are seen as a major growth driver in the U.S. healthcare sector. Experts cited by CNBC note that increased penetration of these treatments could have "gradual effects on healthcare services inflation," a key metric monitored by the Federal Reserve. Furthermore, the impact extends beyond pharmaceuticals, potentially altering healthcare consumption patterns and labor productivity.

This expansion comes amid intense competition in the obesity drug market, largely dominated by Novo Nordisk. Investors are closely watching the effects of these treatments on the profit margins of the health sector and the valuations of major pharmaceutical companies. Eli Lilly's stock saw a 1.9% increase on Monday, contributing to an approximate 11.3% rise in June.